Pradaxa Lawsuit Update: Next Status Conference in Federal Pradaxa Litigation Scheduled for December 13th, Bernstein Liebhard LLP Reports

Share Article

Bernstein Liebhard LLP is now evaluating potential Pradaxa lawsuits on behalf of patients who experienced life-threatening bleeding, allegedly due to Pradaxa.

Bernstein Liebhard LLP | Consumer Injury Lawyers
We continue to hear from Pradaxa patients who experienced frightening episodes of internal bleeding while using this blood thinner. We are pleased to see that the federal Pradaxa litigation is moving forward.

Pradaxa lawsuits continue to move forward in the federal multidistrict litigation currently underway in U.S. District Court, Southern District of Illinois, Bernstein Liebhard LLP reports. According to court records, the next Status Conference in the Pradaxa litigation is scheduled for December 13, 2012. Pradaxa lawsuits pending in the Southern District of Illinois allege Boehringer Ingelheim Pharmaceuticals, Inc. failed to provide adequate warnings about the risk for life-threatening Pradaxa bleeding, especially the lack of an effective reversal agent for hemorrhaging in Pradaxa patients. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)

“We continue to hear from Pradaxa patients who experienced frightening episodes of internal bleeding while using this blood thinner. We are pleased to see that the federal Pradaxa litigation is moving forward,” says Bernstein Liebhard LLP, a national law firm representing clients who have been injured by dangerous drugs and defective medical devices. The firm is currently offering free and confidential lawsuit evaluations to victims of Pradaxa bleeding side effects.

Pradaxa Lawsuits
Pradaxa, which is used to prevent strokes in people with a heart-rhythm disorder known as atrial fibrillation, was approved by the U.S. Food & Drug Administration (FDA) in October 2010, and was intended to be a replacement for decades-old warfarin. While both warfarin and Pradaxa can cause serious internal hemorrhaging, warfarin bleeding can be stopped via the administration of vitamin k. However, there is no readily available antidote for Pradaxa bleeding. Dialysis can be used to remove Pradaxa from the blood stream. However, a study published in May in the journal, Neurology, found this treatment is risky and may not be administered in enough time to stop Pradaxa bleeding.*

According to an article recently published by USA Today, the FDA received 3,781 adverse event reports last year involving Pradaxa, including 542 deaths among patients using the blood thinner. No other drug monitored by the agency outpaced Pradaxa during that period, according to the report.**

Court records indicate that some 138 Pradaxa bleeding lawsuits are currently pending in the Southern District of Illinois. Victims of serious Pradaxa bleeding may be eligible to collect compensation for their medical bills, lost wages, pain and suffering and more. To learn more about filing a Pradaxa lawsuit, please visit our website, or call 1-877-779-1414 to speak with one of our Pradaxa lawyers today.


About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.


Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website